secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2024-10-10T23:59:59+00:00
Accession:  0001193125-24-236039
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 5.02, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase raises ~$110M in private placement; appoints four new directors
--------------------------------------------------------------------------

- Gross proceeds ~$110M from common stock, pre-funded warrants, and Series A-1/B-1 warrants at $1.37 per share unit.
- Company to seek stockholder approval to increase authorized shares; meeting within 90 days of close of offering.
- Board expands from 5 to 7; appoints Bellini, Munshi, Kush, Canner effective Oct 21.
- Series A-1 warrants ($1.37) expire 30 days after Phase 2b safety readout; Series B-1 ($1.49) after efficacy readout.
- New directors invest alongside: BSquared $2M, Munshi family $500K, Kush trust $200K, Soleus Capital ~$21.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312524236039/0001193125-24-236039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312524236039/d882121d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-236039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer